Ultimovacs
Menu Close ✕
  • About
    • About Ultimovacs
    • Team
    • Board of directors
  • Technology
    • Technology overview
    • Immunotherapy
    • Clinical studies
  • Investors
    • Shares
    • Financial reports
    • Presentations and Publications
    • Investor relations contacts
    • Analyst coverage
    • Governance
    • News
  • Contact

Enabling the immune system to fight cancer

Ultimovacs is a pharmaceutical company developing novel immunotherapies against cancer.

Read more about Ultimovacs

Our mission is to extend and improve the life of patients by directing the immune system against the core of cancer.

We will provide universally accessible solutions.

Tweets | @Ultimovacs

See all

Press Releases

Ultimovacs ASA: Second quarter 2021 result presentation 20, August, 2021
Ultimovacs Announces Further Positive Topline Results from Phase I UV1 Cancer Vaccine Combination Study in Metastatic Melanoma 12, August, 2021
Ultimovacs ASA: Invitation to second quarter 2021 results webcast presentation 11, August, 2021
Ultimovacs announces first patient enrolled in Phase II FOCUS trial of UV1 in head-and-neck cancer 5, August, 2021
Ultimovacs Announces Review Article Highlighting Telomerase-based Therapeutic Cancer Vaccines 5, July, 2021
Ultimovacs ASCO Phase I data shows 60% ORR in advanced melanoma with UV1/pembrolizumab, supporting broad Phase II combination program 4, June, 2021
See all

News

Finansavisen – Topline results 12, August, 2021
Open position as Head of Investor Relations and Communication 5, July, 2021
Presentation at LifeSci Nordic Biotech Summit Tuesday 29 June 2021 28, June, 2021
Biostock article on Ultimovacs’ clinical data presented at ASCO 8, June, 2021
ASCO data – HealthTalk interview with CMO Jens Bjørheim 7, June, 2021
Company update on Ultimovacs after the release of clinical data, has been published by Edison Investment Research 21, May, 2021
See all
E-mail: mail@ultimovacs.com
Phone number: +47 413 80 080
Ullernchausséen 64
0379 Oslo
Norway View in Google Maps

Technology

  • Technology
  • Clinical studies
  • Immunotherapy

Ultimovacs

  • About Ultimovacs
  • Team
  • Board of directors
  • Contact us

Investors

  • Share information
  • Financial reports
  • Investor relations contacts
  • News
Copyright © Ultimovacs ASA 2021